CD44S-hyaluronan Interactions Protect Cells Resulting from EMT Against Anoikis

Overview

Journal Matrix Biol

Publisher Elsevier

Specialties Biochemistry
Molecular Biology

Date 2015 May 5

PMID 25937513

Citations 18

Authors

Benjamin Cieply

Colton Koontz

Steven M Frisch

Affiliations

Soon will be listed here.

Abstract

The detachment of normal epithelial cells from matrix triggers an apoptotic response known as anoikis, during homeostatic turnover. Metastatic tumor cells evade anoikis, by mechanisms that are only partly characterized. In particular, the epithelial-mesenchymal transition (EMT) in a subset of invasive tumor cells confers anoikis-resistance. In some cases, EMT up-regulates the cancer stem cell marker CD44S and the enzyme hyaluronic acid synthase-2 (HAS2). CD44S is the major receptor for hyaluronan in the extracellular matrix. Herein, we demonstrate that CD44S, unlike the CD44E isoform expressed in normal epithelial cells, contributes to the protection against anoikis. This protection requires the interaction of CD44S with hyaluronan (HA). CD44S-HA interaction is proposed to play an important role in tumor metastasis through enhanced cell survival under detached conditions.

Citing Articles

Effects of Hyaluronan on Breast Cancer Aggressiveness.

Parnigoni A, Moretto P, Viola M, Karousou E, Passi A, Vigetti D Cancers (Basel). 2023; 15(15).

PMID: 37568628 PMC: 10417239. DOI: 10.3390/cancers15153813.

How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy.

Nasr M, Lynch C Cancer Metastasis Rev. 2023; 42(4):1133-1146.

PMID: 37442876 PMC: 10713810. DOI: 10.1007/s10555-023-10124-z.

Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments.

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X Mol Cancer. 2023; 22(1):48.

PMID: 36906534 PMC: 10007858. DOI: 10.1186/s12943-023-01744-8.

'Two-faces' of hyaluronan, a dynamic barometer of disease progression in tumor microenvironment.

Liu Y, Li L, Wang L, Lu L, Li Y, Huang G Discov Oncol. 2023; 14(1):11.

PMID: 36698043 PMC: 9877274. DOI: 10.1007/s12672-023-00618-1.

In Silico Design and Selection of New Tetrahydroisoquinoline-Based CD44 Antagonist Candidates.

Ruiz-Moreno A, Reyes-Romero A, Domling A, Velasco-Velazquez M Molecules. 2021; 26(7).

PMID: 33810348 PMC: 8037692. DOI: 10.3390/molecules26071877.

References

Toole B, Slomiany M . Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist Updat. 2008; 11(3):110-21. PMC: 2584579. DOI: 10.1016/j.drup.2008.04.002. View

Louderbough J, Schroeder J . Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011; 9(12):1573-86. DOI: 10.1158/1541-7786.MCR-11-0156. View

Zoller M . CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med (Berl). 1995; 73(9):425-38. DOI: 10.1007/BF00202261. View

Melrose J, Tammi M, Smith S . Visualisation of hyaluronan and hyaluronan-binding proteins within ovine vertebral cartilages using biotinylated aggrecan G1-link complex and biotinylated hyaluronan oligosaccharides. Histochem Cell Biol. 2002; 117(4):327-33. DOI: 10.1007/s00418-002-0392-4. View

Petrey A, de la Motte C . Hyaluronan, a crucial regulator of inflammation. Front Immunol. 2014; 5:101. PMC: 3949149. DOI: 10.3389/fimmu.2014.00101. View

Xu X, Chen Y, Chen J, Yang S, Gao F, Underhill C . A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res. 2003; 63(18):5685-90. View

Dave B, Mittal V, Tan N, Chang J . Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012; 14(1):202. PMC: 3496111. DOI: 10.1186/bcr2938. View

Marangoni E, Lecomte N, Durand L, De Pinieux G, Decaudin D, Chomienne C . CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br J Cancer. 2009; 100(6):918-22. PMC: 2661796. DOI: 10.1038/sj.bjc.6604953. View

Wielenga V, Smits R, Korinek V, Smit L, Kielman M, Fodde R . Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999; 154(2):515-23. PMC: 1850011. DOI: 10.1016/S0002-9440(10)65297-2. View

10.

Frisch S, Schaller M, Cieply B . Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci. 2013; 126(Pt 1):21-9. PMC: 3603508. DOI: 10.1242/jcs.120907. View

11.

van Weering D, Baas P, Bos J . A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl. 1993; 3(2):100-6. DOI: 10.1101/gr.3.2.100. View

12.

Brabletz T . EMT and MET in metastasis: where are the cancer stem cells?. Cancer Cell. 2012; 22(6):699-701. DOI: 10.1016/j.ccr.2012.11.009. View

13.

Creighton C, Li X, Landis M, Dixon J, Neumeister V, Sjolund A . Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A. 2009; 106(33):13820-5. PMC: 2720409. DOI: 10.1073/pnas.0905718106. View

14.

Takahashi E, Nagano O, Ishimoto T, Yae T, Suzuki Y, Shinoda T . Tumor necrosis factor-alpha regulates transforming growth factor-beta-dependent epithelial-mesenchymal transition by promoting hyaluronan-CD44-moesin interaction. J Biol Chem. 2009; 285(6):4060-4073. PMC: 2823547. DOI: 10.1074/jbc.M109.056523. View

15.

Godar S, Ince T, Bell G, Feldser D, Liu Donaher J, Bergh J . Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008; 134(1):62-73. PMC: 3222460. DOI: 10.1016/j.cell.2008.06.006. View

16.

Sansonetti A, Bourcier S, Durand L, Chomienne C, Smadja-Joffe F, Robert-Lezenes J . CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. Leuk Res. 2011; 36(3):358-62. DOI: 10.1016/j.leukres.2011.09.022. View

17.

Warzecha C, Jiang P, Amirikian K, Dittmar K, Lu H, Shen S . An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO J. 2010; 29(19):3286-300. PMC: 2957203. DOI: 10.1038/emboj.2010.195. View

18.

Cieply B, Riley 4th P, Pifer P, Widmeyer J, Addison J, Ivanov A . Suppression of the epithelial-mesenchymal transition by Grainyhead-like-2. Cancer Res. 2012; 72(9):2440-53. PMC: 3342427. DOI: 10.1158/0008-5472.CAN-11-4038. View

19.

Brown R, Reinke L, Damerow M, Perez D, Chodosh L, Yang J . CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121(3):1064-74. PMC: 3049398. DOI: 10.1172/JCI44540. View

20.

Legg J, Lewis C, Parsons M, Ng T, Isacke C . A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol. 2002; 4(6):399-407. DOI: 10.1038/ncb797. View